Separate names with a comma.
Discussion in 'Shire' started by anonymous, Jul 10, 2018 at 11:06 AM.
this was a May article
no truth dickhead
Fuck you troll.... just trying to get an honest perspective.... Pussy’s like yourself were probably bullied, like a lil bitch back in school..... LMAO
No we bullied red neck hillbillys like you. Your Mother a half breed meth head and your lazy coward Daddy was a drunk and unemployed bum like you.
The writing is on the wall...The OBU is going to be gone soon. Numbers are stagntic and they have way too many reps in the field. And the product isn’t even new anymore! Needs to be sold to a true ophthalmic company with good managed care if they want it to be a $2 billion drug.
If you truly don’t believe that the OBU will be gone soon then you are in the perfect job. A job that requires zero skill, knowledge or strategy. Puppets who are given a script and call plan. Any moron can do the job. I bet you even complain about how hard the job is and that driving 45 minutes is challenging your ability to balance family and work life. For the love of god please be my competition when interviewing for another job when we all get canned.
WTF are you even talking about.
My gues it will happen before the acquisition. To make Shire more affordable for Takeda. It will be interesting to see who is actually still here, at the POA meeting in Sept.
Heard Novartis/Alcon will be purchasing Xiidra (the product NOT the business unit). Good luck keeping your job!
Novartis is clearly very interested in dry eye.
that is why we focused everything around a 90 Day script. Make as much money now before generic restasis and this Takeda deal.
Everyone is interested in Dry Eye and Everyone remotely associated with Ophthalmology wants to get in the space. Big $$ potential, even if half the market will be generic Restasis. Look at the glaucoma market for insight into the future of Dry Eye drops. Alcon may want to launch their own brand vs taking over a product that's been out for 2+ years. Lots of baggage with Xiidra, but Takeda/Shire may want to sell cheap to get out from underneath it at this point. Who knows! Biotech companies are madly trying to develop "non drop" alternatives across most of the disease states in Ophthalmology anyway, so it may be a short term game anyway!!
It will never hit $2 billion let alone $1. It’s pretty much at its peak. There are too many competitors coming to market soon.